Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.12 HKD | +0.36% | +0.54% | -9.59% |
04-05 | Everbest Machinery Industry to Set Up 30 Million Yuan Joint Venture | MT |
03-26 | Yunkang Swings to Loss in 2023; Recommends Dividend | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company sustains low margins.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.59% | 854M | - | ||
-17.89% | 8.25B | B+ | ||
+39.20% | 3.57B | C+ | ||
-39.11% | 2.46B | B- | ||
-8.06% | 2.46B | - | ||
-7.35% | 2.38B | B- | ||
-12.61% | 1.81B | C- | ||
-19.01% | 1.55B | A- | ||
-40.66% | 1.21B | C+ | ||
+7.56% | 1.11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2325 Stock
- Ratings Yunkang Group Limited